American Research & Management Company’s GMAC Capital Trust I 8.125% Fixed Rate/Floating Rate Trust Preferred Securities, Series 2 ALLY.PRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-1,446
Closed -$36K 401
2021
Q3
$36K Sell
1,446
-7,952
-85% -$208K 0.01% 226
2021
Q2
$236K Sell
9,398
-10,695
-53% -$273K 0.05% 119
2021
Q1
$512K Hold
20,093
0.12% 92
2020
Q4
$544K Buy
20,093
+1,918
+11% +$49.7K 0.14% 90
2020
Q3
$454K Hold
18,175
0.13% 83
2020
Q2
$407K Hold
18,175
0.12% 90
2020
Q1
$373K Buy
+18,175
New +$449K 0.14% 92

American Research & Management Company's ALLY.PRA Position: Q4 2021 in Review

American Research & Management Company sold out of GMAC Capital Trust I 8.125% Fixed Rate/Floating Rate Trust Preferred Securities, Series 2 (ALLY.PRA) in Q4 2021, closing a stake of 1,446 shares — an estimated $36K sold.

American Research & Management Company first reported a position in ALLY.PRA in Q1 2020 and held it in 7 quarters. The position peaked at $544K in Q4 2020. 0 funds tracked by Wall St. Rank hold ALLY.PRA as of Q4 2021.

  • American Research & Management Company reported no remaining GMAC Capital Trust I 8.125% Fixed Rate/Floating Rate Trust Preferred Securities, Series 2 position as of Q4 2021 after selling out during the quarter.
  • American Research & Management Company sold 1,446 GMAC Capital Trust I 8.125% Fixed Rate/Floating Rate Trust Preferred Securities, Series 2 shares in Q4 2021, an estimated $36K.
  • American Research & Management Company first reported a position in GMAC Capital Trust I 8.125% Fixed Rate/Floating Rate Trust Preferred Securities, Series 2 in Q1 2020 and held it in 7 quarters.
  • American Research & Management Company's GMAC Capital Trust I 8.125% Fixed Rate/Floating Rate Trust Preferred Securities, Series 2 position peaked at $544K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held GMAC Capital Trust I 8.125% Fixed Rate/Floating Rate Trust Preferred Securities, Series 2 as of Q4 2021.

Based on American Research & Management Company's 13F filing for Q4 2021, filed 28 Jan 2022.